Bristol Myers Squibb says ZENBEXUS combo cuts multiple myeloma progression risk 51% in Phase 3 EXCALIBER-RRMM trial
BMY•Bristol Myers Squibb reported positive topline Phase 3 EXCALIBER-RRMM results, saying ZENBEXUS with daratumumab and dexamethasone cut the risk of multiple myeloma progression by 51%. The regimen extended time without disease worsening versus a standard-of-care comparator.
1. Positive trial results
Bristol Myers Squibb reported positive topline Phase 3 EXCALIBER-RRMM results for ZENBEXUS combined with daratumumab and dexamethasone in relapsed multiple myeloma. The regimen cut the risk of disease progression by 51% and extended time without disease worsening versus a standard-of-care comparator.
2. Data presentation planned
Detailed data are scheduled for presentation at the American Society of Hematology annual meeting. ZENBEXUS has accelerated U.S. clearance in this setting, with continued marketing dependent on confirmatory clinical benefit from trials such as EXCALIBER-RRMM.
